Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Boehringer Ingelheim
Johnson and Johnson
Colorcon
Medtronic

Last Updated: September 25, 2022

ENDOMETRIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Endometrin patents expire, and what generic alternatives are available?

Endometrin is a drug marketed by Ferring and is included in one NDA.

The generic ingredient in ENDOMETRIN is progesterone. There are fifty-seven drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the progesterone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Endometrin

A generic version of ENDOMETRIN was approved as progesterone by FRESENIUS KABI USA on April 25th, 2001.

  Try it Free

Drug patent expirations by year for ENDOMETRIN
Drug Prices for ENDOMETRIN

See drug prices for ENDOMETRIN

Drug Sales Revenue Trends for ENDOMETRIN

See drug sales revenues for ENDOMETRIN

Recent Clinical Trials for ENDOMETRIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
The University of Hong KongPhase 3
Meir Medical CenterN/A
Assaf-Harofeh Medical CenterPhase 4

See all ENDOMETRIN clinical trials

Pharmacology for ENDOMETRIN
Drug Class Progesterone

US Patents and Regulatory Information for ENDOMETRIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ferring ENDOMETRIN progesterone INSERT;VAGINAL 022057-001 Jun 21, 2007 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ENDOMETRIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ferring ENDOMETRIN progesterone INSERT;VAGINAL 022057-001 Jun 21, 2007 See Plans and Pricing See Plans and Pricing
Ferring ENDOMETRIN progesterone INSERT;VAGINAL 022057-001 Jun 21, 2007 See Plans and Pricing See Plans and Pricing
Ferring ENDOMETRIN progesterone INSERT;VAGINAL 022057-001 Jun 21, 2007 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ENDOMETRIN

See the table below for patents covering ENDOMETRIN around the world.

Country Patent Number Title Estimated Expiration
Spain 2390959 See Plans and Pricing
Denmark 1131052 See Plans and Pricing
Japan 2002529494 See Plans and Pricing
Japan 4667601 See Plans and Pricing
Taiwan I239249 See Plans and Pricing
Japan 2011026335 PROGESTERONE-CONTAINING TABLET FOR TRANSVAGINAL ADMINISTRATION, AND PREPARATION METHOD THEREOF See Plans and Pricing
Canada 2568823 COMPRIMES DE PROGESTERONE A ADMINISTRATION VAGINALE ET METHODE DE PREPARATION (VAGINALLY ADMINISTRABLE PROGESTERONE-CONTAINING TABLETS AND METHOD FOR PREPARING SAME) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ENDOMETRIN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2782584 LUC00245 Luxembourg See Plans and Pricing PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17SS-ESTRADIOL), EVENTUELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (Y COMPRIS SOUS FORME HEMIHYDRATEE), ET DE LA PROGESTERONE; AUTHORISATION NUMBER AND DATE: BE582231 20210701
2782584 301153 Netherlands See Plans and Pricing PRODUCT NAME: COMPOSITION CONTAINING BOTH ESTRADIOL (17SS-ESTRADIOL), OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE OR SOLVATE THEREOF (INCLUDING IN HEMIHYDRATE FORM), AND PROGESTERONE; NATIONAL REGISTRATION NO/DATE: RVG 125821 20210611; FIRST REGISTRATION: BE BE582231 20210406
2782584 132021000000197 Italy See Plans and Pricing PRODUCT NAME: ESTRADIOLO (17SS-ESTRADIOLO) IN PARTICOLARE NELLA FORMA EMIIDRATA, E PROGESTERONE COMPRENDENTI LE VARIE FORME DI ESTRADIOLO (17SS-ESTRADIOLO), QUALI LE FORME IDRATE E SOLVATATE, INCLUDENDO LA FORMA EMIIDRATA, ED I SUOI SALI.(BIJUVA); AUTHORISATION NUMBER(S) AND DATE(S): BE582231, 20210406;048335018 -048335020, 20210517
0113964 97C0037 Belgium See Plans and Pricing PRODUCT NAME: OESTROGENES EQUINS CONJUGUES; ACETATE DE MEDROXYPROGESTERONE; NAT. REGISTRATION NO/DATE: NL 19569 19950301; FIRST REGISTRATION: CH - 52647 01 010 19940826
2782584 2021C/558 Belgium See Plans and Pricing PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17--ESTRADIOL), EVENTUELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (Y COMPRIS SOUS FORME HEMIHYDRATEE), ET DE LA PROGESTERONE; AUTHORISATION NUMBER AND DATE: BE582231 20210406
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
McKinsey
Harvard Business School
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.